Drug & intervention

apalutamide

RxCUI 1999574

Clinical trials93
Recruiting17
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

40 shown
Study of Oral MRT-2359 With Apalutamide in Prostate CancerNCT07745361 · 2026-08-01
RECRUITING
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04
RECRUITING
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialNCT06931340 · 2025-12-01
RECRUITING
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology ClinicsNCT07406282 · 2025-07-22
RECRUITING
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28
RECRUITING
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate CancerNCT07002320 · 2025-04-28
RECRUITING
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PETNCT06758882 · 2024-11-25
RECRUITING
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.NCT06274047 · 2024-09-10
RECRUITING
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialNCT06378866 · 2024-06-03
RECRUITING
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE TrialNCT06067269 · 2024-03-28
RECRUITING
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate CancerNCT06095089 · 2023-11-01
RECRUITING
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerNCT05818683 · 2023-04-26
RECRUITING
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.NCT05422911 · 2022-08-31
RECRUITING
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerNCT04947254 · 2021-08-05
RECRUITING
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingNCT04423211 · 2020-10-08
RECRUITING
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerNCT05406999 · 2020-02-01
RECRUITING
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerNCT03903835 · 2019-02-01
RECRUITING
A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerNCT07783282 · 2026-08-31
NOT_YET_RECRUITING
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)NCT07086651 · 2025-07-21
COMPLETED
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET StudyNCT06430411 · 2024-05-31
NOT_YET_RECRUITING
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyNCT05960578 · 2024-05-23
ACTIVE_NOT_RECRUITING
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United StatesNCT06204302 · 2024-01-05
COMPLETED
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World SettingsNCT06013475 · 2023-08-31
COMPLETED
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCNCT05884398 · 2023-08-31
ACTIVE_NOT_RECRUITING
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or EnzalutamideNCT05901649 · 2023-07-05
COMPLETED
Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT TreatmentNCT05717582 · 2023-05-01
NOT_YET_RECRUITING
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate CancerNCT05751941 · 2023-02-14
ACTIVE_NOT_RECRUITING
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007 · 2023-02-13
COMPLETED
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerNCT05367440 · 2022-06-02
ACTIVE_NOT_RECRUITING
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World SettingsNCT05362149 · 2022-04-04
COMPLETED
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerNCT05212857 · 2022-04-01
UNKNOWN
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT05295927 · 2022-03-23
TERMINATED
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerNCT04926181 · 2022-03-16
TERMINATED
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication CompletelyNCT05202301 · 2022-01-15
COMPLETED
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone MetastasesNCT05740488 · 2022-01-07
UNKNOWN
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate GlandNCT04530552 · 2021-07-23
COMPLETED
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerNCT04662580 · 2021-05-03
ACTIVE_NOT_RECRUITING
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerNCT03902951 · 2021-03-17
ACTIVE_NOT_RECRUITING
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerNCT04666129 · 2021-02-18
COMPLETED
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate CancerNCT04997252 · 2021-02-01
UNKNOWN

Conditions being studied

Prostate Cancer29Prostatic Neoplasms14Prostate Adenocarcinoma10Stage IVB Prostate Cancer AJCC v87Stage IVA Prostate Cancer AJCC v86Metastatic Prostate Carcinoma5Metastatic Hormone-sensitive Prostate Cancer4Metastatic Prostate Cancer4Non-Metastatic Castration-Resistant Prostate Cancer4Stage IV Prostate Adenocarcinoma AJCC v74Stage IV Prostate Cancer AJCC v84Biochemically Recurrent Prostate Carcinoma3Castration-Resistant Prostate Cancer3Castration-Resistant Prostate Carcinoma3Stage II Prostate Cancer AJCC v83Stage III Prostate Cancer AJCC v83Stage IIIA Prostate Cancer AJCC v83Cancer of the Prostate2Castration Levels of Testosterone2Castration-Sensitive Prostate Carcinoma2

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.